These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 6124326)

  • 61. Metabolic and haemodynamic effects and pharmacokinetics of a new selective beta 1-adrenoceptor agonist, prenalterol, in man.
    Rönn O; Fellenius E; Graffner C; Johnsson G; Lundborg P; Svensson L
    Eur J Clin Pharmacol; 1980 Feb; 17(2):81-6. PubMed ID: 6102914
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Prenalterol in the treatment of orthostatic hypotension in Shy-Drager syndrome.
    Goovaerts J; Verfaillie C; Knockaert D; Fagard R; Fiocchi R; Amery A; Lijnen P
    Acta Cardiol; 1984; 39(2):147-55. PubMed ID: 6145274
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Comparative effects of prenalterol and dobutamine in a canine model of acute ischemic heart failure.
    Kirlin PC; Pitt B; Lucchesi BR
    J Cardiovasc Pharmacol; 1981; 3(4):896-905. PubMed ID: 6167819
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Circulatory effects of prenalterol (selective beta-1 agonist) in normal subjects and in patients with primary congestive cardiomyopathy].
    Moruzzi P; Cipolla CM; Bartorelli A; Reggiani P; Lu Quo Ging ; Guazzi M
    Cardiologia; 1982; 27(1):99-101. PubMed ID: 6892381
    [No Abstract]   [Full Text] [Related]  

  • 65. Hemodynamic and cardiometabolic effects of prenalterol in patients with gram negative septic shock.
    Reiz S; Friedman A
    Acta Anaesthesiol Scand; 1980; 24(1):5-10. PubMed ID: 7376804
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Intravenous and oral prenalterol in congestive heart failure. Effects on systemic and coronary hemodynamics and myocardial catecholamine balance.
    Wahr DW; Swedberg K; Rabbino M; Hoyle MJ; Curran D; Parmley WW; Chatterjee K
    Am J Med; 1984 Jun; 76(6):999-1005. PubMed ID: 6731471
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Noninvasive assessment of chronotropic and inotropic response to preferential beta-1 and beta-2 adrenoceptor stimulation.
    Corea L; Bentivoglio M; Verdecchia P; Motolese M; Sorbini CA; Grassi V; Tantucci C
    Clin Pharmacol Ther; 1984 Jun; 35(6):776-81. PubMed ID: 6145533
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Prenalterol as a diagnostic test in patients with pseudoischaemic T waves.
    Capucci A; Pacassoni D; Cavallini C; Magnani B
    Int J Clin Pharmacol Res; 1984; 4(3):185-94. PubMed ID: 6149196
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Regional myocardial contractile response to the beta-adrenergic stimulant prenalterol in the conscious dog following myocardial infarction. Mechanism of hemodynamic effect.
    Kirlin PC; Romson JL; Pitt B; Lucchesi B
    Pharmacology; 1984; 28(1):51-60. PubMed ID: 6701187
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Lack of effect of prenalterol on dialysis-associated hypotension.
    Ladefoged J
    Eur J Clin Pharmacol; 1984; 26(3):399-400. PubMed ID: 6145594
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Acute effects of beta 1 agonism with prenalterol on catecholamine circulating levels in patients with congestive heart failure.
    Corea L; Bentivoglio M; Verdecchia P; Provvidenza M
    G Ital Cardiol; 1983 Nov; 13(11):330-4. PubMed ID: 6141975
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The immediate haemodynamic and electrophysiological response to prenalterol during fixed rate pacing in patients with chronic ischaemic heart disease.
    Sire S; Amlie JP; Simonsen S
    Acta Pharmacol Toxicol (Copenh); 1986 Jan; 58(1):43-8. PubMed ID: 3953293
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Effects of prenalterol and its N-homoveratryl derivative in the anaesthetized cat.
    Maccarrone C; Malta E; Raper C
    Naunyn Schmiedebergs Arch Pharmacol; 1983 Jul; 323(3):245-50. PubMed ID: 6621718
    [No Abstract]   [Full Text] [Related]  

  • 74. [Electrophysiological effects of prenalterol on sinus function in coronary disease patients].
    Bolognesi R; Cucchini F; Giacometti P; Sartori M; Zeppellini R; Javernaro A; Potenza D
    Cardiologia; 1982; 27(2):219-22. PubMed ID: 6892413
    [No Abstract]   [Full Text] [Related]  

  • 75. A dose response study with oral prenalterol in patients with chronic congestive cardiac failure.
    Hendry WG; Comerford MB; Besterman EM
    Clin Cardiol; 1984 Jan; 7(1):23-8. PubMed ID: 6705284
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Haemodynamic effects of prenalterol in patients on dialysis.
    Lustenberger N
    Acta Med Scand Suppl; 1982; 659():157-67. PubMed ID: 6127886
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Electrophysiological studies with prenalterol.
    Weisswange A; Csapo G; Kalusche D; Keck M
    Acta Med Scand Suppl; 1982; 659():123-36. PubMed ID: 6127883
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [2 case reports. The use of prenalterol as an antidote to massive overdosage with beta blockaders].
    Kulling P; Eleborg L; Persson H
    Lakartidningen; 1982 Feb; 79(7):518-20. PubMed ID: 6123634
    [No Abstract]   [Full Text] [Related]  

  • 79. Reversal of hypotension and bradycardia with prenalterol.
    Ostergaard D; Hüttemeier P; Pedersen T
    Anaesthesia; 1984 May; 39(5):494-5. PubMed ID: 6145369
    [No Abstract]   [Full Text] [Related]  

  • 80. [Prenalterol (Hyprenan). A new cardiotonic agent].
    Pelle H; Svendsen TL; Kampmann JP
    Ugeskr Laeger; 1982 Dec; 144(49):3688-90. PubMed ID: 6133384
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.